Healthcare > Pharmaceuticals & Biotechnology
•770 stocks
•
Total Market Cap: Loading...
Market Cap Distribution
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (770)
%
| Company | Market Cap | Price |
|---|---|---|
|
Immunome operates as a biotechnology company focused on oncology, aligning with the Biotech - Oncology category.
|
$1.21B |
$13.92
-5.18%
|
|
CureVac's pipeline centers on oncology immunotherapies and cancer vaccines (off-the-shelf and personalized), aligning with Biotech - Oncology.
|
$1.21B |
$5.38
-0.74%
|
|
Maze develops oral small molecule therapeutics (MZE829, MZE782) for CVRM/renal diseases, which fits the 'Oral Small Molecule Therapeutics' category.
|
$1.20B |
$27.43
-4.62%
|
|
ModeX's Epstein–Barr Virus (EBV) vaccine candidate constitutes a Vaccine product development program.
|
$1.20B |
$1.51
-3.21%
|
|
HEPLISAV-B is a hepatitis B vaccine and the pipeline includes multiple vaccine candidates, directly aligning with the Vaccines category.
|
$1.20B |
$9.96
-3.49%
|
|
Deucrictibant is an oral small-molecule therapeutic intended for on-demand and prophylactic treatment of hereditary and acquired angioedema.
|
$1.19B |
$21.98
-3.21%
|
|
Ardelyx directly develops and commercializes oral small-molecule therapeutics (tenapanor) for IBS-C (IBSRELA) and hyperphosphatemia (XPHOZAH).
|
$1.18B |
$4.94
-2.18%
|
|
Wave Life Sciences develops RNA-based therapeutics and gene-editing approaches (AIMers, allele-selective therapies), directly matching gene therapy as its core offering.
|
$1.17B |
$7.60
-8.21%
|
|
Company operates in oncology diagnostics; classification under biotech-oncology.
|
$1.17B |
$9.10
+1.56%
|
|
HCAd gene therapy platform and PCRX-201 OA program, plus the GQ Bio Therapeutics acquisition, anchor a gene-therapy product pipeline.
|
$1.17B |
$25.24
-2.28%
|
|
NBTXR3 is an oncology nanotherapeutic asset, directly produced/distributed by Nanobiotix as a lead product.
|
$1.12B |
$23.60
-10.91%
|
|
RLY-2608 is described as an oral small molecule therapeutic, aligning with Oral Small Molecule Therapeutics.
|
$1.11B |
$6.50
-5.80%
|
|
Direct product category: Haduvio is an oral small molecule therapeutic (nalbuphine ER) targeting chronic cough.
|
$1.11B |
$8.95
+2.17%
|
|
Biosimilars: Amphastar's pipeline includes AMP-004 (insulin aspart) and AMP-028, positioning the company in the biosimilars category.
|
$1.11B |
$23.63
-5.52%
|
|
Neffy is a needle-free intranasal delivery drug using a proprietary delivery platform, representing a major drug delivery platform product.
|
$1.11B |
$11.32
-3.25%
|
|
Lead product is a monoclonal antibody targeting active C1s to inhibit the classical complement pathway for rare autoimmune and inflammatory diseases.
|
$1.11B |
$34.46
-1.06%
|
|
Direct products Jornay PM, Belbuca, Xtampza ER, and Nucynta ER/IR are small‑molecule prescription therapeutics; tag corresponds to the major product category these Rx therapies belong to (Oral Small Molecule Therapeutics).
|
$1.11B |
$34.22
-0.55%
|
|
LENZ directly develops and markets an ophthalmic drug (VIZZ) indicated for presbyopia, fitting Ophthalmic Drugs as the core product category.
|
$1.09B |
$38.79
-17.03%
|
|
GIAPREZA is a cardiovascular drug marketed by Innoviva's Specialty Therapeutics platform; direct product sales in this category.
|
$1.09B |
$17.35
-0.91%
|
|
Core immunology therapeutics addressing autoimmune diseases via Treg stimulation (REZPEG).
|
$1.08B |
$58.85
+2.65%
|
|
Company focuses on oncology immunotherapies, aligning with Biotech - Oncology.
|
$1.07B |
$10.36
-5.39%
|
|
Verekitug is an immunology-focused therapeutic targeting the TSLP receptor, aligning with Immunology Therapeutics.
|
$1.06B |
$19.62
-0.91%
|
|
Neuropsychiatric drug development is a core focus, including rapid-acting CNS/psychiatric therapies.
|
$1.05B |
$5.23
+1.16%
|
|
Septerna's core focus is discovery and development of oral small-molecule therapeutics targeting GPCRs (platform-enabled drug discovery).
|
$1.03B |
$23.07
+5.20%
|
|
Company develops oncology therapeutics (taletrectinib and safusidenib) and is active in cancer drug development, fitting Biotech - Oncology.
|
$1.02B |
$3.20
+5.26%
|
|
Direct product: TSHA-102 is a gene therapy using an AAV9 vector designed to address Rett syndrome.
|
$1.01B |
$4.81
+1.91%
|
|
Verve Therapeutics is developing in vivo gene-editing therapies (GalNAc-LNP delivery) to permanently modify liver-expressed targets like PCSK9, ANGPTL3, and Lp(a).
|
$988.30M |
$11.13
|
|
Spyre Therapeutics is focused on immunology therapeutics and antibody-based treatments for inflammatory diseases (IBD, RA), aligning with the Immunology Therapeutics category.
|
$987.38M |
$16.32
-0.28%
|
|
ORIC is a clinical-stage oncology-focused biotechnology company with lead cancer therapies (ORIC-944, ORIC-114) and an oncology-focused development roadmap.
|
$972.48M |
$13.68
-2.84%
|
|
Pharming operates as a large-cap pharmaceutical company with core products RUCONEST and Joenja and a growing rare-disease pipeline.
|
$968.01M |
$14.27
-3.58%
|
|
Rapport Therapeutics develops targeted small-molecule therapies for neurological and psychiatric disorders, fitting Neuropsychiatric Drug Development.
|
$967.19M |
$26.50
-1.08%
|
|
Zenas BioPharma's lead asset obexelimab is a monoclonal antibody therapeutic
|
$963.44M |
$23.03
+5.84%
|
|
Enliven Therapeutics is a biotech focused on oncology with lead oral small molecule inhibitors, placing it in Biotech - Oncology.
|
$962.25M |
$19.61
-2.34%
|
|
Precigen's core programs are gene therapies (e.g., PRGN-2012), aligning with Biotech - Gene Therapy.
|
$959.34M |
$3.25
-3.85%
|
|
Lead asset is an ophthalmic drug (DURAVYU) delivered via a sustained-release implant for wet AMD and DME.
|
$956.48M |
$13.90
+4.91%
|
|
Lead candidate ficerafusp alfa is an oncology biotech therapy targeting EGFR and TGF-β, placing Bicara squarely in Biotech - Oncology.
|
$929.30M |
$17.04
+1.97%
|
|
Rosnilimab and ANB033/ANB101 are monoclonal antibody therapeutics in AnaptysBio's wholly-owned immunology pipeline.
|
$921.67M |
$31.37
-2.15%
|
|
MM120 and MM402 programs target CNS/psychiatric conditions, fitting Neuropsychiatric Drug Development.
|
$892.28M |
$11.81
-5.75%
|
|
OCS is focused on developing ophthalmic drugs, including OCS-01 and OCS-02, for eye diseases.
|
$884.62M |
$21.09
-1.91%
|
|
Core product is an autologous cell therapy (rilparencel) targeting kidney disease, directly aligning with Cell Therapy as a primary business line.
|
$883.96M |
$3.02
-8.48%
|
|
Fortrea is a standalone CRO providing outsourced clinical development services.
|
$870.75M |
$9.68
-10.83%
|
|
Praxis' Cerebrum platform develops orally administered small-molecule therapeutics (e.g., ulixacaltamide, vormatrigine, relutrigine).
|
$859.98M |
$47.67
-1.37%
|
|
Kura Oncology is a focused oncology biotech developing ziftomenib and other cancer therapies, directly aligning with Biotech - Oncology.
|
$852.76M |
$9.85
-4.09%
|
|
Embecta provides contract manufacturing services and co-packaging partnerships with partners.
|
$834.00M |
$14.47
+1.47%
|
|
Imdusiran (AB-729) is a proprietary RNA interference therapeutic directly developed by Arbutus for chronic HBV, making RNAi therapeutics a core product category.
|
$831.23M |
$4.34
-1.14%
|
|
VOQUEZNA (vonoprazan) is an oral small molecule therapeutic (P-CAB) marketed as the core product for GERD and H. pylori therapy.
|
$825.20M |
$11.82
+0.17%
|
|
Core focus on gene therapy/gene editing workflows via nucleic acid production inputs and related technologies (CleanCap, Poly(A+) tail mods, CleanScribe).
|
$812.36M |
$3.19
-3.92%
|
|
Imetelstat is an oligonucleotide-based telomerase inhibitor used to treat hematologic malignancies (lower-risk MDS) and is Geron's lead therapeutic.
|
$808.89M |
$1.27
+0.39%
|
|
URGN's core business is oncology-focused biotech/drug development, including UGN-102 (ZUSDURI) and pipeline assets.
|
$802.27M |
$17.40
+0.87%
|
|
Lead Alzheimer's disease therapeutic (blarcamesine) directly aligns with Alzheimer's Disease Therapeutics.
|
$791.40M |
$9.27
-1.80%
|
|
Datapoints is a contract research organization (CRO) providing outsourced research/data services.
|
$791.35M |
$13.52
-12.04%
|
|
Tango Therapeutics is a clinical-stage biotechnology company focused on precision oncology, developing novel cancer therapies (synthetic lethality and immune evasion) with lead small-molecule inhibitors.
|
$773.93M |
$7.14
-3.64%
|
|
Palvella Therapeutics focuses on rare genetic skin diseases (microcystic LMs and cutaneous VMs) with its QTORIN topical rapamycin platform, which aligns with the Biotech - Rare Diseases investable theme.
|
$772.79M |
$69.90
+1.29%
|
|
Radioligand Therapy: radiopharmaceutical isotopes used for targeted cancer therapies.
|
$760.38M |
$10.13
+14.21%
|
|
Olema develops oral small-molecule therapeutics, including palazestrant (OP-1250) and OP-3136.
|
$759.48M |
$11.10
-0.36%
|
|
Dual-masked T-cell engagers constitute bispecific antibody therapeutics with engineered safety profiles.
|
$758.93M |
$5.49
+5.98%
|
|
Directly develops HIP-modified cell therapies (SC451) and other ex vivo engineered cell products, the core business line.
|
$753.35M |
$3.34
-1.47%
|
|
Nurix is a clinical-stage oncology-focused biotech developing targeted protein degradation therapies (BTK degraders) for cancer.
|
$746.15M |
$9.76
+0.51%
|
|
Prime Medicine's core focus is gene-editing therapies (Prime Editing) intended as one-time curative genetic medicines, i.e., gene therapy.
|
$745.75M |
$5.68
-9.55%
|
|
Amtagvi lifileucel is an autologous tumor-infiltrating lymphocyte (TIL) cell therapy, the company's core product.
|
$737.99M |
$2.25
+2.04%
|
|
Xencor's XmAb platform centers on engineered bispecific antibodies (e.g., XmAb2+1 formats) and a pipeline of T-cell engager therapies.
|
$735.19M |
$10.33
-0.29%
|
|
OJEMDA (tovorafenib) is a systemic oncology therapy directly developed and commercialized by the company.
|
$733.86M |
$7.24
-3.34%
|
|
KE is a contract manufacturer providing outsourced electronics and medical device manufacturing services.
|
$729.22M |
$29.91
+1.08%
|
|
Melinta Therapeutics' product portfolio (including antibiotics) positions CorMedix as a Large Cap Pharma company with a diversified infectious-disease drug line.
|
$727.76M |
$10.73
-2.28%
|
|
Vafseo (vadadustat) is Akebia's core product and is an oral small-molecule therapeutic (HIF-PHI) for CKD-related anemia, aligning with the 'Oral Small Molecule Therapeutics' tag.
|
$722.25M |
$2.75
-4.84%
|
|
Valneva directly develops, manufactures, and commercializes vaccines (IXIARO, DUKORAL, IXCHIQ) and has Lyme, chikungunya, Shigella, and Zika vaccine candidates in its pipeline, representing its core product category.
|
$720.26M |
$10.37
-3.62%
|
|
Biotech - Oncology: diagnostics and tests focused on cancer risk, profiling, and management.
|
$709.77M |
$7.72
+0.78%
|
|
Rezolute is focused on ultra-rare diseases, with its lead asset ersodetug targeting hyperinsulinism disorders.
|
$707.24M |
$8.27
-6.02%
|
|
Ampreloxetine is an orally administered small-molecule therapeutic in Phase 3, representing a core product category for Theravance Biopharma.
|
$699.52M |
$13.99
-3.12%
|
|
Gyre Therapeutics is a fibrosis-focused biotech developing and commercializing anti-fibrotic therapies (ETUARY pirfenidone derivative, Hydronidone/F351, Nintedanib, Avatrombopag) and pursuing global liver-fibrosis indications, aligning with the Biotech - Rare Diseases theme.
|
$694.74M |
$7.41
-2.50%
|
|
SunOpta operates as a co-manufacturer and private-label partner for brands and retailers, aligning with Contract Manufacturing Organizations.
|
$691.15M |
$5.88
+0.51%
|
|
TYRA Biosciences is a clinical-stage biotech focused on oncology therapies, notably selective FGFR inhibitors.
|
$689.72M |
$12.97
+3.10%
|
|
ERAS is a biotech company focused on oncology; its core mission and pipeline target cancer therapies, placing it under Biotech - Oncology.
|
$685.56M |
$2.42
+13.08%
|
|
Contract Research Organizations—bioPharma services and clinical trial support.
|
$685.29M |
$22.51
-1.01%
|
|
TERN's pipeline consists of small-molecule, oral therapeutics (e.g., TERN-701 and TERN-601), classifying the company under Oral Small Molecule Therapeutics.
|
$680.36M |
$7.61
-2.31%
|
|
ArriVent BioPharma develops oncology therapeutics, including lead asset firmonertinib, placing it in Biotech - Oncology.
|
$678.78M |
$19.84
+5.42%
|
|
Company's focus centers on oncology-related diagnostics (dermatologic cancers, Barrett's esophagus), placing it in biotech oncology diagnostics.
|
$666.37M |
$23.08
-3.11%
|
|
Company is developing neuropsychiatric drug therapeutics targeting CNS/psychiatric indications (depression, TRD, bipolar disorder, postpartum depression).
|
$655.03M |
$12.59
-4.48%
|
|
Aquestive's PharmFilm/Adrenaverse drug delivery platform enables non-invasive dissolvable oral films (Anaphylm, Libervant) and supports pipeline products like AQST-108.
|
$649.60M |
$6.54
-2.24%
|
|
Duchenne muscular dystrophy (DMD) and myelodysplastic syndromes (MDS) are rare diseases, and Keros' assets target these indications via TGF-β pathway modulation.
|
$637.66M |
$15.70
-2.73%
|
|
Core business: the company develops and commercializes gene therapies (AAV-GAD, AAV2-hAQP1, AIPL1) and a proprietary riboswitch platform.
|
$630.06M |
$7.84
-11.11%
|
|
Kodiak directly develops ophthalmic drugs (intravitreal biologics) for retinal diseases.
|
$626.30M |
$11.87
-11.42%
|
|
Company focuses on oncology programs using Molecular Glue Degraders (MGDs), aligning with Biotech - Oncology.
|
$617.56M |
$10.04
+17.02%
|
|
Zevra Therapeutics is vertically focused on developing and commercializing therapies for rare diseases (NPC, UCDs, VEDS, IH/narcolepsy), directly aligning with Biotech - Rare Diseases.
|
$602.02M |
$11.01
+0.18%
|
|
SIGA's TPOXX is a small-molecule antiviral drug, placing the company in Antiviral Small-Molecule Therapeutics.
|
$587.25M |
$8.22
-2.72%
|
|
CMPX develops proprietary bispecific antibodies (e.g., tovecimig, CTX-8371, CTX-10726), the core product category they directly design and advance.
|
$586.32M |
$4.24
+4.18%
|
|
Savara's focus is on rare respiratory diseases (e.g., autoimmune pulmonary alveolar proteinosis) and orphan lung conditions.
|
$582.46M |
$3.37
-1.75%
|
|
The company is focused on neuropsychiatric drug development, specifically psychedelic-based therapeutics for mental health conditions.
|
$581.95M |
$6.22
-4.31%
|
|
Company focuses on proprietary oncology therapeutics using Bicycle molecule platform.
|
$576.19M |
$8.32
-7.25%
|
|
KalVista's EKTERLY (sebetralstat) is an orally delivered small molecule therapeutic approved for acute HAE attacks, directly matching the 'Oral Small Molecule Therapeutics' investable theme.
|
$574.47M |
$11.50
-2.54%
|
|
Lead candidate soquelitinib is an oral small molecule therapeutic, representing Corvus's core product line.
|
$569.88M |
$7.39
+11.30%
|
|
MBX directly develops peptide-based therapeutics under its Precision Endocrine Peptide platform, fitting the Peptide Therapeutics category.
|
$557.85M |
$16.69
-0.36%
|
|
Arvinas' lead programs target cancer (ER degrader vepdegestrant, BCL6 degrader ARV-393, KRAS G12D degrader ARV-806) using PROTACs; core oncology product line.
|
$548.90M |
$7.52
-2.59%
|
|
REGENXBIO's core business revolves around NAV gene therapy platform and its in-house gene therapy product candidates (RGX-121, RGX-202, ABBV-RGX-314), mapping to Biotech - Gene Therapy.
|
$547.75M |
$10.92
-9.83%
|
|
MoonLake's lead asset Sonelokimab is an immunology therapeutic targeting inflammatory diseases (HS, PsA, etc.).
|
$541.24M |
$8.43
+11.95%
|
|
Lexicon's pipeline consists of oral small-molecule therapeutics (pilavapadin LX9211, LX9851, sotagliflozin) and it generates revenue from INPEFA, classifying as an oral small-molecule therapeutics business.
|
$541.14M |
$1.49
-10.24%
|
|
Core business involves monoclonal antibody therapeutics targeting neurodegenerative diseases (e.g., PRX012) and related pipeline assets.
|
$540.96M |
$10.05
-2.80%
|
|
Direct oncology-focused biotech product line via MNPR-101 platform and cancer-targeted radiopharmaceuticals.
|
$537.04M |
$87.82
-14.34%
|
|
Eton is focused on ultra-rare disease therapies (ALKINDI SPRINKLE, INCRELEX, GALZIN, and pipeline ET-400/ET-600/ET-700/ET-800), aligning with the Biotech - Rare Diseases investable theme.
|
$534.47M |
$19.93
+0.66%
|
|
Seralutinib is a small-molecule therapeutic drug in development for pulmonary hypertension, representing a core drug modality.
|
$518.25M |
$2.28
-10.59%
|
Showing page 3 of 8 (770 total stocks)
Loading industry metrics...
Loading comparison data...
